Carcinogen-DNA and protein adducts: Biomarkers for cohort selection and modifiable endpoints in chemoprevention trials

Journal of Cellular Biochemistry

Volumn 63, Issue SUPPL. 25, 1996, Pages 85-91

  Kensler, Thomas W ^a   Groopman, John D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

aflatoxin albumin adducts; aflatoxin N7 guanine; biologically effective dose; hepatocarcinogenesis; oltipraz

Indexed keywords

AFLATOXIN; DNA; OLTIPRAZ; TUMOR MARKER; 2,3 DIHYDRO 2 (N(7) GUANYL) 3 HYDROXYAFLATOXIN B1; 2,3-DIHYDRO-2-(N(7)-GUANYL)-3-HYDROXYAFLATOXIN B1; AFLATOXIN B1; ANTINEOPLASTIC AGENT; CARCINOGEN; DRUG DERIVATIVE; GUANINE; PROTEIN; PYRAZINE DERIVATIVE;

ARTICLE; CARCINOGEN DNA INTERACTION; CHEMICAL CARCINOGENESIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; AGED; COHORT ANALYSIS; DNA ADDUCT; HEPATITIS B; LIVER TUMOR; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; REVIEW; RISK FACTOR; URINE;

AFLATOXIN B1; AFLATOXINS; AGED; ANTICARCINOGENIC AGENTS; CARCINOGENS; CLINICAL TRIALS; COHORT STUDIES; DNA ADDUCTS; GUANINE; HEPATITIS B; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEINS; PYRAZINES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030498084     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(1996)25+<85::AID-JCB12>3.0.CO;2-M     Document Type: Article

References (30)

1. Hulka BS, Wilosky TC, Griffith JD (eds) (1990): "Biological Markers in Epidemiology." New York: Oxford Press.
2. Schulte PA, Perera FP (eds) (1993): "Molecular Epidemiology: Principles and Practices." San Diego: Academic Press.
3. Mendelsohn ML, Peeters JP, Normandy MJ (eds) (1995): "Biomarkers and Occupational Health: Progress and Perspectives." Washington, DC: Joseph Henry Press.
4. Links JM, Kensler TW, Groopman JD (1995): Biomarkers and mechanistic approaches in environmental epidemiology. Annu Rev Public Health 16:83-103.
5. Groopman JD, Kensler TW (1993): Molecular biomarkers for human chemical carcinogen exposures. Chem Res Toxicol 6:764-770.
6. International Agency for Research on Cancer (1993): Aflatoxins. IARC Monogr Eval Carcinog Risks Hum 56:245-395.
7. Groopman JD, Cain LG, Kensler TW (1988): Aflatoxin exposure in human populations: Measurements and relationships to cancer. CRC Crit Rev Toxicol 19:113-145.
8. Wild CP, Jiang YZ, Sabbioni G, Chapot B, Montesano R (1990): Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. Cancer Res 50:245-251.
9. 1-treated rats. Cancer Res 41:650-654.
10. 7-guanine and other aflatoxin metabolites by multiple monoclonal antibody affinity chromatography and HPLC. Cancer Res 52:267-274.
11. 7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats. Carcinogenesis 13:101-106.
12. 1 binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis 7:853-858.
13. 1 in vivo in rats. Carcinogenesis 8:819-824.
14. Groopman JD, Zhu J, Donahue PR, Pikul A, Zhang L-S, Chen J-S, Wogan GN (1992): Molecular dosimetry of urinary aflatoxin DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res 52:45-51.
15. 1. Carcinogenesis 9:1323-1325.
16. 7-guanine in human urine obtained in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1:221-228.
17. Wild CP, Hudson G, Sabbioni G, Wogan GN, Whittle H, Montesano R, Groopman JD (1992): Correlation of dietary intake of aflatoxin with the level of albumin bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1:229-234.
18. Hall AJ, Wild CP (1994): Epidemiology of aflatoxin-related disease. In Eaton DL, Groopman JD (eds): "The Toxicology of Aflatoxins." San Diego: Academic Press, pp 233-258.
19. Campbell TC, Chen J, Liu C, Li J, Parpia B (1990): Nonassociation of aflatoxin with primary liver cancer in a cross-sectional ecological survey in the People's Republic of China. Cancer Res 50:6882-6893.
20. Ross RK, Yuan J-M, Yu MC, Wogan GN, Qian G-S, Tu J-T, Groopman JD, Gao Y-T, Henderson BE (1992): Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339:943-946.
21. Qian G-S, Ross RK, Yu MC, Yuan J-M, Gao Y-T, Headerson BE, Wogan GN, Groopman JD (1994): A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 3:3-10.
22. Kensler TW, Davis EF, Bolton MG (1994): Strategies for chemoprotection against aflatoxin-induced liver cancer. In Eaton DL, Groopman JD (eds): "The Toxicology of Aflatoxins." San Diego: Academic Press, pp 281-306.
23. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): Predictive role for short-term molecular dosimetry. Cancer Res 51. 5501-5506.
24. Egner PA, Gange, SJ, Dolan PM, Groopman JD, Muñoz A, Kensler TW (1995): Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis 16:1769-1773.
25. Bolton MG, Mun̈oz A, Jacobson LP, Groopman JD, Maxuitenko YY, Roebuck BD, Kensler TW (1993): Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. Cancer Res 53: 3499-3504.
26. Primiano TP, Egner PA, Sutter TR, Kelloff GJ, Roebuck BD, Kensler TW: Intermittent dosing with oltipraz: Relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res 55:4319-4324.
27. Zhu Y-R, Chen J-G, Huang XY (1989): Hepatocellular carcinoma in Qidong County. In Tang ZY (ed): "Primary Liver Cancer." China Academic Publisher, Springer Verlag, pp 204-222.
28. Wang J-S, Qian J-S, Zhu Y-R, Zarba A, Muñoz A, Kensler TW, Groopman JD (1995): Temporal patterns and persistence of aflatoxin-albumin adducts in residents of Daxin Township, Qidong, P.R.C. Proc Am Assoc Cancer Res 36:282.
29. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994): Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
30. Jacobson LP, Zhang B-C, Zhu Y-R, Wang J-B, Wu Y, Zhang Q-N, Yu Y-L, Qian G-S, Kuang S-Y, Li Y-F, Fang X, Zarba A, Chen B, Enger CL, Davidson NE, Gordon GB, Gorman MB, Prochaska HJ, Egner PA, Groopman JD, Muñoz A, Helzlsouer KJ and Kensler TW (1996): Oltipraz chemoprevention trial in Qidong, People's Republic of China: Study design and clinical outcomes. Cancer Epi. Biomarkers Prev., in press.